Skip to content

Tarlatamab for Treatment of Small Cell Lung Cancer in Clinical Practice: A Multicenter U.S. Retrospective Cohort Study from the ONWARD consortium.

Nov 2026 · Journal of Thoracic Oncology · pp. 106243 · 0 citations
Medicine

Abstract

Background

Real-world data on efficacy and safety of tarlatamab in small cell lung cancer (SCLC) remains limited.

Methods

This retrospective study analyzed 265 tarlatamab-treated patients across 11 U.S. centers in the ONWARD-SCLC consortium (11/2023-4/2025), evaluating clinical outcomes, CRS, ICANS, and impact of prophylactic medications.

Results

Median age was 66 years; 87.2% had ECOG 0-1, 90.6% had de novo SCLC, and 44.5% and 39.2% had new/progressive brain and liver metastases before tarlatamab, respectively. Median prior lines of therapy were 2 (range 0-6). At a median follow-up of 4.9 months, DCR was 52.6% for evaluable SCLC cohort (all-treated: 37.9%). Median rw-PFS and rw-OS were 2.3 and 8.0 months. Median rw-PFS was 2.2 months among patients without brain metastasis versus 2.3 months among those with pre-existing brain metastasis (p=0.542). Following Cycle 1 Day 1 (C1D1), CRS occurred in 40.8% (Grade 3-4: 3.8%) and ICANS in 21.5% (Grade 3-4: 6%), with incidence declining markedly on subsequent doses. Compared to no-prophylaxis (N=237), prophylactic tocilizumab (N=19) was associated with lower CRS (5.3% vs. 43.0%; adj. p=0.017), ICANS (0% vs 22.4%; adj. p=0.041), and "prolonged hospitalization" rate (21.1% vs. 54.9%; adj. p=0.023). Multivariable analysis identified insulin-dependent diabetes, liver metastases, number of prior treatments, recent urgent care admissions, and low albumin/elevated ALT as independent predictors of worse OS.

Conclusion

Tarlatamab demonstrated meaningful clinical activity in pretreated real-world cohort, including those with brain metastases. Grade ≥3 CRS and overall/grade ≥3 ICANS incidence in C1 were higher than in clinical trials. Prophylaxis patterns were characterized and warrant prospective validation.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.